JNJoaniter Immaculate Nankabirwa

Joaniter Immaculate Nankabirwa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joaniter Immaculate Nankabirwa has a total of 349 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Low Birthweight and Prematurity, but not Malaria Chemoprevention, Are Associated With Reduced Pneumococcal Vaccine Immunogenicity in Ugandan Infants

    by Kenneth Musinguzi, Alyssa N Sbarra, Florian Bach, Felistas Nankya, Karen Bino Achom, Caroline Mwubaha, Patience Nayebare, Evelyn Nansubuga, Abel Kakuru, Jimmy Kizza, et al.

    Background: Malaria exposure has been hypothesized to alter immune responses to childhood vaccines, but evidence is inconsistent. We evaluated whether early-life malaria exposure and perennial malaria chemoprevention (PMC) modify antibody responses to the 10-valent pneumococcal conjugate vaccine (PCV-10) among infants in a high malaria transmission setting in eastern Uganda. Methods: This study was nested within the MIC-DroP trial (NCT04978272) whereby 202 infants were selected for inclusion. Serotype-specific IgG concentrations were measured using an in-house multiplex seroassay from samples obtained at 8 and 24 weeks of age. Immunogenicity was quantified as the log10 fold-change in IgG concentration between the 8- and 24-week timepoints, and seroconversion as ≥0.35 μg/mL at week 24 (ie, seropositive). Generalized estimating equation models were used to assess associations of PCV-10 immunogenicity and seroconversion with malaria exposure, malaria chemoprevention, and birth outcomes. Results: Among the 195 of 202 infants who completed the three-dose PCV-10 series, neither infant PMC nor malaria exposure from study enrollment to 14 weeks were associated with PCV-10 immunogenicity or seroconversion. In contrast, low birthweight (<2500 g) was associated with lower immunogenicity (82% lower [95% confidence interval (CI): 43–94%] antibody fold-change, P = .003) and reduced odds of seroconversion (OR = 0.19 [95% CI: 0.06–0.57], P = .003); preterm birth (<37 weeks) showed similar associations (79% lower [95% CI: 24–94%] antibody fold-change, P = .018; OR = 0.181 [95% CI: 0.05–0.65], P = .009). Conclusions: In this malaria-endemic setting, early-life malaria exposure and chemoprevention did not measurably alter PCV-10 antibody responses. However, low birthweight and prematurity were associated with reduced vaccine immunogenicity.

  • Open Access

    Low birthweight and prematurity, but not malaria chemoprevention, are associated with reduced pneumococcal vaccine immunogenicity in Ugandan infants

    by Kenneth Musinguzi, Alyssa N Sbarra, Florian Bach, Felistas Nankya, Karen Bino Achom, Caroline Mwubaha, Patience Nayebare, Evelyn Nansubuga, Abel Kakuru, Jimmy Kizza, et al.

    Background: Malaria exposure has been hypothesized to alter immune responses to childhood vaccines, but evidence is inconsistent. We evaluated whether early-life malaria exposure and perennial malaria chemoprevention (PMC) modify antibody responses to the 10-valent pneumococcal conjugate vaccine (PCV-10) among infants in a high malaria transmission setting in eastern Uganda. Methods: This study was nested within the MIC-DroP trial ( NCT04978272 ) whereby 202 infants were selected for inclusion. Serotype-specific IgG concentrations were measured using an in-house multiplex seroassay from samples obtained at 8 and 24 weeks of age. Immunogenicity was quantified as the log 10 fold-change in IgG concentration between the 8 and 24-week timepoints, and seroconversion as ≥0.35 μg/mL at week 24 (i.e., seropositive). Generalized estimating equation models were used to assess associations of PCV-10 immunogenicity and seroconversion with malaria exposure, malaria chemoprevention and birth outcomes. Results: Among the 195 of 202 infants who completed the three-dose PCV-10 series, neither infant PMC nor malaria exposure from study enrollment to 14 weeks were associated with PCV-10 immunogenicity or seroconversion. In contrast, low birthweight (<2500g) was associated with lower immunogenicity (82% lower antibody fold-change, p=0.003) and reduced odds of seroconversion (OR=0.19, p=0.003); preterm birth (<37 weeks) showed similar associations (79% lower antibody fold-change, p=0.018; OR=0.181, p=0.009). Conclusion: In this malaria-endemic setting, early-life malaria exposure and chemoprevention did not measurably alter PCV-10 antibody responses. However, low birthweight and prematurity were associated with reduced vaccine immunogenicity.


  • Open Access

    CXCR6+ CD127– Tr1 cells balance immunity and persistence in Plasmodium falciparum infection

    by Jason Nideffer, Florian Bach, Steven Strubbe, Luis Lopez, Maato Zedi, Felistas Nankya, Jessica Briggs, Kattria van der Ploeg, Kenneth Musinguzi, Soyeon Kim, et al.

    Plasmodium falciparum ( Pf ) induces the clonal expansion of antigen-specific type 1 regulatory T (Tr1) cells capable of long-term memory. Tr1 cells comprise nearly 90% of the Pf blood stage antigen-specific CD4+ T cell pool in children. Though, whether Tr1 cells contribute to protection from malaria remains undetermined. To address this critical knowledge gap, we first performed scRNA-seq on gated cell populations and validated CXCR6+ CD127- as new phenotypic markers to enrich for bona-fide Tr1 cells. Importantly, these Tr1 cells potently suppressed the proliferation of other CD4+ T cells in vitro via IL-10 secretion. Among children living in malaria-endemic Uganda, CXCR6+ CD127- Tr1 cells were the dominant responding subset to Pf -infected red blood cell stimulation in vitro. They also rapidly expanded following malaria and expressed IL-10 and IFNγ during infection in vivo. Tr1 abundance correlated with plasma concentrations of granzyme A, IFNγ, IL-10, and LAG3, suggesting that these cells act systemically. Higher CXCR6+ CD127- Tr1 cell frequencies correlated with a lower probability of symptoms given parasitemia but were also associated with delayed parasite clearance among untreated, asymptomatic children. These data suggest that Tr1 cells help mediate clinical immunity to malaria but may also facilitate parasite persistence through mechanisms of immune regulation.


  • Open Access

    Impact of Intermittent Preventive Treatment for Malaria in Pregnancy With Sulfadoxine-Pyrimethamine, Dihydroartemisinin-Piperaquine, and Their Combination on Infant Outcomes: A Randomized Controlled Trial

    by Joaniter I Nankabirwa, Abel Kakuru, Anna T Nguyen, Michelle E Roh, Miriam Aguti, Harriet Adrama, Jimmy Kizza, Peter Olwoch, Kylie Camanag, Jade Benjamin-Chung, et al.

    Background: Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine (IPTp-DP) is more effective than sulfadoxine-pyrimethamine (IPTp-SP) at reducing the burden of malaria in pregnancy. Paradoxically, IPTp-DP has been associated with lower birth weights compared with IPTp-SP. Whether the impacts of IPTp-DP extend after birth is unknown. Methods: We conducted a double-blind randomized controlled trial to compare malaria burden and growth among infants born to mothers who were randomized to monthly IPTp-SP, IPTp-DP, or IPTp-DP + SP. Infants were followed to 12 months of age by passive and active surveillance. The primary outcome was clinical malaria incidence; secondary outcomes included parasite prevalence and infant growth outcomes. Results: Among 871 infants enrolled, there were 667 episodes of clinical malaria. Compared to infants whose mothers received IPTp-SP, malaria incidence was similar in infants whose mothers received IPTp-DP (incidence rate ratio [IRR] 1.04, 95% CI .78–1.38) or IPTp-DP + SP (IRR = 0.93, 95% CI .68–1.26). Overall parasite prevalence at monthly visits was 21.8%. Parasite prevalence was also similar between groups. The prevalence of wasting at birth was higher in infants whose mothers received IPTp-DP + SP (prevalence ratio [PR] = 2.30, 95% CI 1.07–4.97) or IPTp-DP (PR = 2.25, 95% CI 1.03–4.94) than those that received IPTp-SP, but differences between groups resolved by 3–6 months of age. Conclusions: There were no significant differences in infant outcomes between the 3 IPTp arms apart from a transiently increased risk of wasting among infants born to mothers who received DP-containing IPTp regimens.


  • Open Access

    Pharmacometric Evaluation of Sulfadoxine-Pyrimethamine-Amodiaquine and Dihydroartemisinin-Piperaquine Seasonal Malaria Chemoprevention in Northern Uganda

    by Craig Bonnington, Anthony Nuwa, Katherine Theiss-Nyland, Richard Kajubi, Moses R Kamya, Joaniter Nankabirwa, Christopher Ebong, Jane Nabakooza, Jimmy Opigo, David Salandindi, et al.

    Background: Seasonal malaria chemoprevention (SMC) using monthly sulfadoxine-pyrimethamine-amodiaquine (SPAQ) is being deployed in East Africa, where antimalarial drug-resistance levels are high. Dihydroartemisinin-piperaquine (DP) is a potential alternative. Methods: A prospective 28-day pharmacometric assessment of SMC was conducted in Karamoja, northern Uganda. In 2 villages children received SPAQ and in a third were randomized to DP versus no SMC. The primary outcome was malaria infection defined by capillary blood sample quantitative PCR (qPCR) positivity on day 28, or presentation with fever and slide or rapid test positivity after day 2. Results: Baseline qPCR malaria parasitemia prevalence among 1250 enrolled children was 46% (575/1250); Plasmodium falciparum 85%, other malarias (mainly Plasmodium ovale) 25%. Breakthrough parasitemias occurred in 7% (33/496) of DP, 31% (158/504) of SPAQ, and 39% (98/250) of no drug recipients. Clinical malaria (all P falciparum) developed in 17% of no drug (42/250; 1 severe), 8% of SPAQ (38/504; 2 severe), and 2% of DP (13/496) recipients. Adjusted protective efficacies against all malaria parasitemia, P falciparum parasitemia, and clinical malaria for SPAQ were 56% (95% CI, 35%–70%), 46% (11%–68%), and 60% (27%–78%) and for DP were 84% (77%–89%), 86% (75%–92%), and 86% (74%–92%), respectively. Some asymptomatic P falciparum infections were not cleared by SPAQ. All 260 P falciparum isolates genotyped were PfCRT K76 (haplotype CVMNK, marker of 4-aminoquinoline susceptibility); most were quintuple Pfdhfr/dhps mutants (ie, relatively sulfadoxine-pyrimethamine resistant). The chemoprevention drug exposure–response relationship was strong for desethylamodiaquine, but weak for sulfadoxine. Conclusions: SPAQ SMC had low clinical and parasitological chemopreventive efficacy in northern Uganda, whereas DP was effective. Clinical Trials Registration: NCT05323721.


  • Open Access

    Barriers to reaching the Zero-Dose and Under Immunized Children in Uganda: a qualitative rapid assessment

    by Emmanuel Mugisha, Shadiah Nanteza Mugizi, Deogratias Agaba, Jacqueline Anena, Joanita I. Nankabirwa, Susan Nayiga, Carol Kamya, Faith Namugaya, Paul Katamba, Patrick Albert Ipola, et al.

    Background: Despite great strides made in improving immunization coverage in Uganda, the burden of under-immunized (UI) and zero-dose (ZD) children remains high, increasing the risk of Vaccine Preventable Disease outbreaks. This study explored the barriers to reaching ZD and UI children in selected high-burden communities in Uganda. Methods: This cross sectional qualitative rapid assessment study was conducted in three high-burden districts—Kasese, Mubende, and Wakiso in Uganda The study received ethical approval, and all participants were consented before interview. Data were collected through key informant interviews with local leaders, district health team members, health workers and village health team members, as well as in-depth interviews with caregivers of children aged 18 weeks to 23 months. The collected data were analyzed thematically with the aid of NVIVO 14 (QSR International). Results are presented in themes and subthemes and supported by verbatim quotations where necessary. Results: The study identified a range of demand and supply-side barriers hindering access to immunization for ZD and UI children in Uganda. These barriers are reported under seven themes namely: limited physical access to immunization services; inadequate client-centered immunization services (Long waiting time at health facilities, poor health worker attitudes, immunization-related costs); vaccine stockouts; fear of adverse events following Immunization; limited spousal support; myths and misconceptions related to immunization; and persistent home-based births or deliveries. Conclusion: Understanding the barriers to immunization uptake among zero-dose and under-immunized children is a critical foundation for strengthening vaccination coverage and reducing the incidence of VPDs in Uganda. This rapid assessment conducted in Kasese, Mubende, and Wakiso districts highlights both demand and supply side challenges that hinder access and utilization of immunization services. Addressing these barriers requires coordinated, multi-sectoral approaches that are both comprehensive and contextually grounded.


  • Open Access

    Recurrent Plasmodium falciparum parasitemia and drug resistance mutations during intermittent preventive treatment of malaria in pregnancy in Uganda

    by Jimmy Kizza, Thomas Katairo, Abel Kakuru, Bienvenu Nsengimaana, Trevor Esilu, Innocent Wiringilimaana, Francis D Semakuba, Inna Gerlovina, Nicholas Hathaway, Jessica Briggs, et al.

    Background: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine (IPTp-SP) is recommended during pregnancy in malaria-endemic countries. However, widespread resistance of Plasmodium falciparum to SP has compromised its efficacy, and the alternative dihydroartemisinin-piperaquine (DP) is under study. Potential selection of drug resistance is of interest. Methods: We sequenced 1377 samples collected from pregnant women enrolled in a trial comparing monthly SP, DP, and DP+SP for IPTp in Busia, Uganda and with asymptomatic parasitemia at the time of IPTp administration. We characterized known markers of drug resistance and assessed the 28-day cumulative risk of recurrent parasitemia, with genotyping to distinguish recrudescence from new infections. Results: Among 771 samples collected on the day IPTp was initiated, the prevalences of five resistance mutations in P. falciparum dihydrofolate reductase (PfDHFR) and dihydropteroate synthase (PfDHPS) were nearly 100%, and the PfDHFR I164L and PfDHPS A581G mutations, associated with high-level resistance, had combined prevalence of 26.5%. The cumulative risks of recurrent parasitemia (SP 57.8%, DP 4.1%, DP+SP 3.9%), symptomatic malaria (SP 9.3%, DP 1.1%, DP+SP 0.3%), and recrudescent parasitemia (SP 40.1%, DP 2.0%, DP+SP 0.8%) were all significantly greater in the SP arm, with risks greatest in primigravidae. In the IPT-SP arm, the combined prevalence of the PfDHFR I164L and PfDHPS A581G mutations increased significantly from 24.9% at initiation of IPTp to 35.2% after receipt of IPTp-SP. Infection with mutant parasites was associated with non-significant increases in risks of recrudescence. Conclusions: IPTp-SP had poor preventive efficacy and selected for increased drug resistance, questioning the value of this intervention.


  • Open Access

    Impact of intermittent preventive treatment for malaria in pregnancy with sulfadoxine-pyrimethamine, dihydroartemisinin-piperaquine, and their combination on infant outcomes: A randomized controlled trial

    by Joaniter Immaculate Nankabirwa, Abel Abel, Anna T. Nguyen, Michelle E. Roh, Miriam Aguti, Harriet Adrama, Jimmy Kizza, Peter Olwoch, Kylie Camanag, Jade Benjamin-Chung, et al.


  • Open Access

    Dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine versus either drug alone for intermittent preventive treatment of malaria in pregnancy: A double-blind, randomized, controlled phase 3 trial from Uganda

    by Abel Kakuru, Jimmy Kizza, Miriam Aguti, Harriet Adrama, John Ategeka, Peter Olwoch, Miriam Nakalembe, Joaniter I. Nankabirwa, Bishop Opira, Nida Ozarslan, et al.

    Background: To mitigate adverse consequences of malaria in pregnancy, the World Health Organization recommends intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine–pyrimethamine. However, the effectiveness of IPTp with sulfadoxine–pyrimethamine has been threatened by widespread Plasmodium falciparum resistance, especially in East and Southern Africa. For IPTp, dihydroartemisinin–piperaquine has shown superior antimalarial effects compared to sulfadoxine–pyrimethamine, but sulfadoxine–pyrimethamine has been associated with improved birth outcomes compared to dihydroartemisinin–piperaquine. We hypothesized that a combination of both dihydroartemisinin–piperaquine and sulfadoxine–pyrimethamine would provide superior birth outcomes compared to either drug alone. Methods and findings: We conducted a double-blinded, randomized, controlled trial of 2,757 pregnant women in Uganda, where resistance of malaria parasites to sulfadoxine–pyrimethamine is widespread. Women were randomly assigned (1:1:1) to monthly IPTp with sulfadoxine–pyrimethamine, dihydroartemisinin–piperaquine, or dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine. The primary outcome was the risk of a composite adverse birth outcome defined as any of the following: spontaneous abortion, stillbirth, low birthweight (LBW, < 2,500 g), preterm delivery (p = 0.70) or sulfadoxine–pyrimethamine (30.0% versus 26.4%, RR 1.14 [95% CI 0.98–1.33]; p = 0.10). The risk of a composite adverse birth outcome was higher with dihydroartemisinin–piperaquine compared to sulfadoxine–pyrimethamine (30.9% versus 26.4%, RR 1.17 [95% CI 1.01–1.36]; p = 0.04). Considering individual adverse birth outcomes, combining dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine was associated with a higher risk of small-for-gestational age (23.4% versus 18.7%, RR 1.25 [95% CI 1.04–1.51]; p = 0.02) and low birthweight (8.6% versus 5.8%, RR 1.48 [95 CI 1.04–2.12]; p = 0.03) compared to sulfadoxine–pyrimethamine and a higher risk of preterm delivery (5.3% versus 3.1%, RR 1.73 [95% CI 1.07–2.79]; p = 0.03) compared to dihydroartemisinin–piperaquine. During pregnancy, compared to sulfadoxine–pyrimethamine, dihydroartemisinin–piperaquine was associated with a 94% reduction in the incidence of symptomatic malaria (0.46 versus 0.03 episodes per person-year, incidence rate ratio 0.06 [95% CI 0.03–0.12]; p < 0.001) and a 97% reduction in the risk of microscopic parasitemia (17.7% versus 0.6%, RR 0.03 [95% CI 0.02–0.05]; p < 0.001), but dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine was not associated with improved malaria outcomes over dihydroartemisinin–piperaquine alone. There were no significant differences in the incidence of any grade 3–4 adverse events between the treatment arms. As this study was conducted in an area of high transmission intensity with widespread resistance to sulfadoxine–pyrimethamine, findings may not be generalizable to other settings. Conclusions: Despite the superior antimalarial activity of dihydroartemisinin–piperaquine, sulfadoxine–pyrimethamine alone was associated with improved birth outcomes. Combining dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine for IPTp did not improve birth outcomes compared to either sulfadoxine–pyrimethamine or dihydroartemisinin–piperaquine alone. Trial registration: ClinicalTrials.gov (NCT04336189; https://clinicaltrials.gov/study/NCT04336189).


  • Clone tracking through repeated malaria identifies high-fidelity memory CD4 T cell responses

    by Jason Nideffer, Florian Bach, Felistas Nankya, Kenneth Musinguzi, Šimon Borna, Michelle Mantilla, Maato Zedi, Aracely Garcia Romero, Chloe Gerungan, Nora Yang, et al.

    Few studies have tracked human CD4 + T cell clones through repeated infections. We used longitudinal single-cell RNA and T cell receptor (TCR) tracking to study the functional stability and memory potential of CD4 + T cell clonotypes during repeated Plasmodium falciparum ( Pf ) infections in Ugandan children and adults. Nearly all clonotypes displayed a strong preference for one of seven CD4 + subsets. This phenomenon of “clonal fidelity” was influenced by clonal expansion, linking T cell polarization and proliferation in vivo. Using clone tracking, we characterized subset-specific activation trajectories and identified antigen-specific clones. Type 1 regulatory T (T R 1) cells accounted for nearly 90% of Pf -specific CD4 + T cells in blood. Tracking these clones longitudinally for hundreds of days, we observed malaria-induced expansion of T R 1 effectors, long-term persistence of T R 1 memory cells, and high-fidelity recall responses after reinfection. This work establishes clonal fidelity as a natural phenomenon and demonstrates the stable, long-term memory potential of T R 1 cells.